Pharming Group (PHGUF) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharming Group has reported a strong third quarter in 2024, with total revenues rising by 12% to $74.8 million, driven by growth in its RUCONEST® and Joenja® products. The company’s operating profit also saw a significant increase, and they remain on track to achieve their annual revenue guidance. CEO Sijmen de Vries announced he will step down after a successful 16-year tenure, with a search for his successor underway.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.